Colin Mendelsohn ArchiveAustralian tobacco and vaping policy
Information archive. Not a health service or a shop: no bookings, quotes or dispatch.

Debate over a Cochrane review of e-cigarettes and quitting smoking

Source material dated December 2022 · Research evidence


Overview

This page summarises a 2022 response published in a medical news outlet. It answered an interview in which a commentator criticised a Cochrane review of e-cigarettes for smoking cessation. The source defended the review, argued that its criticisms did not hold, and went on to argue that Australia's prescription-only model had failed. Both sides of the exchange are contested, and this is only the source's side.

Randomised trials and real-world evidence

The source noted that Cochrane reviews of randomised trials are widely treated as a standard for judging treatments, and said the review in question found high certainty evidence that vaping helps people quit more than traditional nicotine replacement. Against the criticism that trials do not reflect real behaviour, it replied that trials are designed to test whether something works in motivated smokers under controlled conditions. It then listed real-world sources, including stop-smoking services, observational studies and national smoking trends, which it said were consistent with the trial results although unable to prove cause.

On long-term cohort studies, the source argued that they often combine people who are not trying to quit with occasional vapers, and reported that studies focusing on daily vapers found quit rates several times higher.

Long-term safety

The source accepted that long-term harm will not be known for decades but pointed to statements from a royal college of physicians and a national health ministry that it described as concluding the harm is very likely much lower than from smoking. It cited lower levels of toxicants in vapour, lower biomarker levels after switching, short clinical trials reporting improved respiratory and cardiovascular measures, and modelling studies estimating a net public health benefit.

Regulation

The article argued that the prescription-only model had been rejected by doctors, vapers and pharmacists, citing low numbers of listed prescribers and of vapers holding a prescription. It proposed an adult consumer model with licensed retailers, strict age verification and severe penalties for sales to minors.

Context and limits

The source's claims about trial design, biomarkers and modelling are contested by other researchers, and the figures it gives reflect 2022. Observational and modelling results do not establish cause, as the source itself acknowledged for part of its argument.

Based on a 2022 opinion article.

This page summarises published material for general information. It reports what a source argued, not the library's own finding, and it is not medical advice or a substitute for advice from a licensed health professional. Details of laws and programs may have changed since the source was written.

Related summaries